Turtle Creek Wealth Advisors LLC Purchases 746 Shares of Stryker Corporation (NYSE:SYK)

Turtle Creek Wealth Advisors LLC lifted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 4.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,306 shares of the medical technology company's stock after purchasing an additional 746 shares during the period. Turtle Creek Wealth Advisors LLC's holdings in Stryker were worth $6,442,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Proficio Capital Partners LLC grew its position in Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock worth $596,000 after purchasing an additional 523 shares in the last quarter. HBK Sorce Advisory LLC grew its position in Stryker by 16.8% during the 4th quarter. HBK Sorce Advisory LLC now owns 807 shares of the medical technology company's stock worth $291,000 after purchasing an additional 116 shares in the last quarter. Picton Mahoney Asset Management grew its position in Stryker by 12.1% during the 4th quarter. Picton Mahoney Asset Management now owns 762 shares of the medical technology company's stock worth $275,000 after purchasing an additional 82 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in Stryker by 16.9% during the 4th quarter. Natixis Advisors LLC now owns 184,817 shares of the medical technology company's stock worth $66,543,000 after purchasing an additional 26,730 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 0.6%

Shares of SYK traded down $2.30 during mid-day trading on Thursday, hitting $388.57. 252,069 shares of the company's stock were exchanged, compared to its average volume of 1,349,145. The company has a market cap of $148.31 billion, a PE ratio of 52.51, a P/E/G ratio of 2.95 and a beta of 0.91. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a 50-day simple moving average of $385.38 and a 200 day simple moving average of $377.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period last year, the company earned $2.50 earnings per share. The business's revenue was up 11.9% compared to the same quarter last year. On average, research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is currently 45.41%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. Evercore ISI lifted their target price on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. BTIG Research restated a "buy" rating on shares of Stryker in a report on Monday. Truist Financial boosted their price target on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a report on Monday, May 5th. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Finally, JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.